AACR 2023 | Blocking IL-4 activity with dupilumab in NSCLC

Thomas Urban Marron, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses findings from a Phase Ib/II trial (NCT05013450) of dupilumab with checkpoint blockade in patients with non-small cell lung cancer (NSCLC). Previous research has suggested blocking IL-4 activity inhibits tumor growth, and the safety and efficacy of dupilumab, an anti-IL-4Ra antibody, was assessed. An encouraging response was reported in biopsies and blood samples, and one patients reported near remission. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.